CAR

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Retrieved on: 
Thursday, November 2, 2023
Multiple myeloma, CAR, Icahn Genomics Institute, Black, Associate, Washington University in St. Louis, Therapy, CRISPR, Genetics, Bone marrow, Icahn School of Medicine at Mount Sinai, Early Prostate Cancer (clinical programme), Translational research, Doctor of Philosophy, Multiple Myeloma Research Foundation, Research, MAC, Stanford University Medical Center, Mount Sinai Health System, University of California, San Francisco, Genomics, Growth, Disease, MMRF, Immunotherapy, University, Gene, Hackensack University Medical Center, San Francisco, Cancer, Patient, Marc, Pharmaceutical industry, Vaccine, MD

NEW YORK, Nov. 2, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Key Points: 
  • Multiple myeloma is a blood cancer that develops in the bone marrow and can spread throughout the body.
  • In 2023, more than 35,000 Americans are projected to be diagnosed with multiple myeloma and approximately 12,000 will lose their lives.
  • Researchers hope to uncover the full landscape of genomic, proteomic and immune differences between high- and standard-risk multiple myeloma patients.
  • "The three exciting programs we selected each have potential to answer fundamental questions about multiple myeloma and help advance rational treatments for this cancer."

ClimeCo Leads Development of First-Ever Low-Carbon Cement Protocol 

Retrieved on: 
Thursday, November 2, 2023
Carbon, Comment, CAR, Global Cement and Concrete Association, Coal, GCCA, ACMS, SCMS, CO2, Portland Cement Association, Cryptocurrency, Cement

BOYERTOWN, Pa., Nov. 2, 2023 /PRNewswire/ -- ClimeCo, a leading global sustainability company, recently leveraged its industrial and methodology expertise to lead the development of Climate Action Reserve's (CAR) new U.S. Low-Carbon Cement Protocol. The protocol establishes a first-of-its-kind pathway to generate voluntary carbon credits from the production of novel and underutilized alternative cementitious materials (ACMs) and supplementary cementitious materials (SCMs). Funds generated by these credits will be used to incentivize the production and scaled use of innovative, less carbon-intensive materials to meet growing demand, reduce emissions and help enable exponential positive change. For more than 18 months, ClimeCo worked closely with numerous stakeholders, including Eco Material Technologies and the Portland Cement Association, to create, seek comment and refine this important effort.

Key Points: 
  • For more than 18 months, ClimeCo worked closely with numerous stakeholders, including Eco Material Technologies and the Portland Cement Association, to create, seek comment and refine this important effort.
  • The new protocol was created to address a pressing emissions crisis in the cement industry.
  • The new protocol was created to address a pressing emissions crisis in the cement industry.
  • "While demand for cement has never been higher, it remains an exceptionally difficult-to-abate industry," said ClimeCo President and CEO Bill Flederbach.

Chroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
MHC, ASH, CAR, Society, CD8, NK, GVHD, Medicine, Therapy, Chroma, Vaccine

BOSTON, Nov. 2, 2023 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology (ASH) 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

Key Points: 
  • BOSTON, Nov. 2, 2023 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology (ASH) 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.
  • The ASH abstract contains data showing the potential of multiplex epigenetic editing to produce functional allogeneic CAR T cells that do not exhibit a graft-versus-host-disease (GVHD) response, resist CD8+ and CD4+ T cell alloresponses, and resist the NK missing-self response normally consequent of reduced MHC class I expression, without introduction of genotoxic events.
  • Details of the poster presentation are:

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Retrieved on: 
Tuesday, October 31, 2023
CAR, Therapy, Society for Immunotherapy of Cancer, CARM, Doctor of Philosophy, Entrepreneurship, SITC, Immunotherapy, Doctor of Pharmacy, Messenger, Annual general meeting, LNP, PT, Society, Cancer, Patient, Myelocyte, Pharmaceutical industry, Vaccine, Mitsubishi Carisma, Moderna

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Key Points: 
  • The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.
  • Accepted as a late-breaking presentation, " In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy ," showcases data that demonstrate Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
  • "We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy," said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna.
  • Details of Carisma data accepted for presentation at the SITC 38th Annual Meeting are as follows:

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Retrieved on: 
Tuesday, October 31, 2023
EGFR, Society for Immunotherapy of Cancer, Neoplasm, CAR, Ovarian cancer, Assistant, CD20, HER2, University, Research, CD69, Mouse, SNAP, SITC, Immunotherapy, Poster, Division, San Diego Convention Center, Cancer, University of Pittsburgh, LAMP1, Leukemia, NSG, Epitope, Society, Therapy, Immunology, Toxic shock syndrome toxin-1, Mobile phone, Vaccine

WEXFORD, Pa., Oct. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, through combinatorial use of different adaptors will be the subject of a poster presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego. 

Key Points: 
  • SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.
  • Further, in another leukemia model targeting the CD20 antigen, SNAP-CAR T cells showed significant inhibition of tumor growth.
  • "While still early in its development, we continue to see vast potential for the SNAP-CAR platform for treating both liquid and solid tumor malignancies."
  • "The data being presented at SITC 2023 encapsulates the groundbreaking research being conducted at the University of Pittsburgh, which demonstrates the potential of SNAP-CAR T-cells to reduce tumor burden and tumor growth in numerous cancers, including HER2-expressing and CD20-expressing cancers," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and Chief Financial Officer

Retrieved on: 
Tuesday, October 31, 2023
CAR, AstraZeneca, Biotechnology, Genetics, Acquisition, MBA, Venture, Yale University, Growth, Partnership, CFO, Cancer, Investment, Corporate development, Management

LOS ANGELES, Oct. 31, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the appointment of Han Lee, Ph.D., MBA, as president and chief financial officer (CFO).

Key Points: 
  • LOS ANGELES, Oct. 31, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the appointment of Han Lee, Ph.D., MBA, as president and chief financial officer (CFO).
  • An accomplished biotechnology executive, Dr. Lee joins ImmPACT Bio with more than 10 years of corporate finance, strategy, business development, and company building experience in the biopharmaceutical industry.
  • "We are thrilled to welcome Han, a seasoned CFO to ImmPACT Bio's executive leadership.
  • This is a pivotal time for ImmPACT Bio with compelling clinical data expected within the next 12 months.

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

Retrieved on: 
Tuesday, October 31, 2023
ASX, Stomach, FDA, CAR, Metastasis, CDH17, IND, Food, Gastrointestinal cancer, University, Doctor of Philosophy, Penns, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glomus tumor, Nature Cancer, Colorectal cancer, Clinical trial, Perelman School of Medicine at the University of Pennsylvania, University of Chicago, Immunotherapy, Cancer, Patient, Toxicity, Neoplasm, CHM, Investigational New Drug, Pharmaceutical industry, Medical imaging, Chimera, MD, Medicine

FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy

Key Points: 
  • FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy
    Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours
    SYDNEY, Oct. 31, 2023 /PRNewswire/ -- Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
  • The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • CHM 2101 is a 3rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • With the FDA IND clearance Chimeric will now begin the initiation of a phase 1 /2 multi-site clinical trial in patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

ImmPACT Bio to Participate in the 2023 Truist Securities BioPharma Symposium

Retrieved on: 
Monday, October 30, 2023
CAR, Cancer

LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023 in New York, NY.

Key Points: 
  • LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023 in New York, NY.
  • Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio's chief executive officer, will participate in a panel discussion entitled "Considerations for an Oncology Company's Autoimmune Side Hustle," on Thursday, November 9, 2023 at 11:40 AM ET.
  • ImmPACT Bio management will also participate in one-on-one investor meetings.
  • To request a one-on-one meeting at the conference, please contact your Truist Securities representative.

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

Retrieved on: 
Thursday, October 26, 2023
News, CAR, Cancer, Kite Pharma, Therapy, PIN, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the market.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the market.
  • The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.
  • The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
  • If you would like the option to ask a question on the conference call, please use this link to register.

Alberta Cancer Foundation announces $10 million in support of cellular therapy excellence

Retrieved on: 
Wednesday, October 25, 2023
Government, CAR, Government House (Alberta), Hope, Health Canada, Research, Engineering, Quality of life, Arthur Beauchesne, Clinical trial, Immune system, Radiation, Cross Cancer Institute, Immunotherapy, Cancer, Patient, Hubley, Neoplasm, Pharmaceutical industry

EDMONTON, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- At a recent BioAlberta event in Edmonton, the Alberta Cancer Foundation announced a major boost for the province’s cellular therapy program – a revolutionary treatment for cancer that has the potential to dramatically improve survival rates for hard-to-treat cancers.

Key Points: 
  • EDMONTON, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- At a recent BioAlberta event in Edmonton, the Alberta Cancer Foundation announced a major boost for the province’s cellular therapy program – a revolutionary treatment for cancer that has the potential to dramatically improve survival rates for hard-to-treat cancers.
  • “Cellular therapy may represent the most significant progress in curing some treatment-resistant cancers in decades.
  • And it’s happening right here, in Alberta,” said Wendy Beauchesne, CEO of the Alberta Cancer Foundation.
  • In 2018, the Alberta Cancer Foundation and the Government of Alberta kickstarted the Alberta Cellular Therapy Program, including a made-in-Alberta clinical trial led by the renowned Dr. Michael Chu.